Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
Scientists at the University of Cambridge created a smarter way to activate the immune system against cancer by harnessing the STING pathway. The new two-part prodrug system triggers the immune response only in tumour tissues, reducing harm to healthy cells.
The University of Texas MD Anderson Cancer Center and Springer Nature will host a free conference on the tumor ecosystem, featuring presentations on cancer immunology, microbiome, disease evolution, and metastasis. Researchers can register for the event and submit abstracts to share their findings.
The study demonstrates the clinical feasibility of simultaneous cell isolation technology, capturing tumor cells and microenvironment cells with high efficiency. The technology improves sensitivity and precision of liquid biopsy, increasing accuracy of early diagnosis and treatment response monitoring.
Research uncovers how glutamate regulates pediatric brain tumor growth, suggesting novel approaches to treating these cancers. Inhibiting glutamate receptors has been shown to reduce human pediatric brain tumor growth in mice.
Breast cancer cells build molecular tunnels into nearby fat cells to release energy, blocking gap junctions stops tumor growth. The discovery provides a golden opportunity for developing effective strategies to treat the most aggressive forms of breast cancer.
Researchers discovered a way to boost T cells' ability to fight cancer by rewiring their energy metabolism. By blocking Ant2 protein, they created a state of heightened readiness and potency in T cells, leading to greater stamina, faster replication, and sharper targeting of cancerous threats.
A team of scientists from the University of Konstanz has identified the PPM1F enzyme as essential for cell migration in both embryonic development and tumor cell invasion. The study found that increased levels of PPM1F enhance the invasive potential of cancer cells, while its absence impairs cell adhesion and migration.
Researchers explore the design of microrobots for targeted cancer therapy, including tumor cell eradication, improved penetration, and immune system modulation. The review also discusses advanced delivery strategies and imaging technologies to enhance treatment efficiency and precision.
A novel fluorescent probe, SLY, has been developed to precisely identify hepatocellular carcinoma tissue using sialylated glycans on the cell surface. The probe outperforms conventional methods by clearly distinguishing tumor margins within liver tissues.
A new urine-based tumor DNA test can help personalize bladder cancer treatment by predicting which patients are at higher risk for recurrence after immunotherapy. The test, UroAmp, analyzes urine samples to identify bladder cancer-related mutations and generate a genomic profile for each patient.
Researchers developed an AI tool called AAnet to characterize cancer cell diversity, identifying five distinct cell groups with different gene expression profiles. This could lead to more targeted therapies and improved patient outcomes.
Researchers discovered dynamic cells coordinate movements to sculpt living tissue in developing fruit flies, highlighting a powerful role of migrating cells in organ formation. This finding suggests similar systems may shape different organs, including the brain and testis.
Researchers developed magnetically driven biohybrid blood hydrogel fibers that can deliver chemotherapy directly to brain tumors while evading the immune system. These fibers exhibit exceptional capability to navigate intricate environments and offer real-time tracking capabilities.
Scientists at UC San Francisco discovered how pancreatic cancer cells metastasize to the lungs or liver using the PCSK9 protein. PCSK9 controls cholesterol acquisition, with low levels favoring the liver and high levels supporting lung adaptation.
Researchers identified C5aR1 as a novel prognostic biomarker and potential therapeutic target for treating metastatic skin cancer. Elevated C5aR1 presence suggests increased metastasis risk and poor survival in patients with cutaneous squamous cell carcinoma.
A study at the University of Zurich tracks live cellular development and epigenetic changes over multiple generations, showing how stress induces heterogeneity and increases genetic complexity. This research may lead to better understanding of cancer cell diversity and develop more effective therapies.
Researchers created a new nanoparticle that combines focused ultrasound and chemotherapy to destroy tumors more precisely and prevent recurrence. The treatment shows promising results in preclinical models, offering a potential breakthrough in cancer therapy.
A systematic review and meta-analysis found that individuals with blood type A have a significantly higher risk of developing breast cancer compared to those with blood type O. The research, which pooled data from over 13,000 breast cancer patients and 717,000 controls, suggests an 18% increased risk associated with blood type A.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer, making them promising for cancer treatment. The study challenges previous perceptions of NK cells, which have historically been considered only innate immune cells with no memory function against cancer.
Long non-coding RNAs (lncRNAs) play a crucial role in regulating the tumor microenvironment, influencing processes such as immune evasion, angiogenesis, and metastasis. They mediate interactions between tumor cells and their surrounding microenvironment, modulating stromal cell activities and promoting tumor growth and survival.
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
Researchers at UC San Diego found that HPV DNA hybridizes with human DNA genes in oropharyngeal cancer cells, forming ecDNA that promotes tumor growth. This study suggests that selectively targeting ecDNA-disrupting therapeutics could slow tumor growth while leaving normal cells intact.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers discovered that a high-fat diet activates mechanisms facilitating breast cancer metastasis by promoting platelet activation and fibronectin expression, creating a fertile breeding ground for tumor cells to take root. This study provides new insights into the relationship between obesity and breast cancer spread.
Researchers have developed a new approach to personalize treatments for young cancer patients by growing tumors in chicken eggs and analyzing proteins. The technique, which combines genomics and proteomics, was successful in identifying a treatment option for a patient with a rare pediatric cancer.
Researchers at St. Jude Children's Research Hospital found that removing the 'signal jammer' protein VDAC2 can improve how tumors respond to immunotherapy. This breakthrough could lead to new ways to enhance immunotherapies and make them more effective in treating resistant cancers.
The project aims to enhance CTC detection sensitivity and specificity for clinical needs in cancer early screening, diagnosis and treatment. The team will develop an integrated system covering CTC counting, classification and downstream detection of CTC proteins and genes.
Researchers create microfluidic device to sort tumor cells based on adhesive strength, revealing potential method to predict aggressive cancer behavior. The study's findings offer a promising approach for personalizing treatment plans and identifying high-risk patients.
Researchers have discovered lipid signatures associated with chemotherapy-resistant cells in colorectal cancer. These lipid alterations can serve as prognostic markers and help develop new treatment strategies to restore drug sensitivity.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
A new nanomedicine, ZnDHT NM, selectively targets cancer stem-like cells (CSCs) and tumor cells, promoting CSC differentiation while inhibiting EMT. This approach also leads to the release of toxic compounds in tumor cells, inducing apoptosis/ferroptosis pathways.
A team of international researchers found that tumor cells become drastically diverse when exiting the bone marrow, affecting immune cells in the cancer lesions. This discovery could contribute to more precise diagnostics and therapy for multiple myeloma, a incurable bone marrow cancer.
A potential new therapy, CT-179, effectively targets tumor cells and disrupts cancer stem cells, leading to improved treatments and increased survival rates. The novel drug, developed by Curtana Pharmaceuticals, may bring new efficacy to brain tumor therapy.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.
Researchers developed a new super-resolution microscopic method to investigate the interactions of therapeutic antibodies with target molecules on tumour cells. The study reveals that all four antibodies crosslink CD20 molecules independently of type I or II classification, and that B cells take on a hedgehog shape after treatment.
Researchers at the University of Alabama at Birmingham have identified HIF1α as a key regulator that induces cancer-killing capacity in T cells under hypoxic conditions. In this study, they found that HIF1α-glycolysis is indispensable for IFN-γ induction in hypoxic T cells.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Researchers develop a method to remove copper from tumor cells, killing them. The nanofibers use copper-binding domains to grasp copper ions, disrupting cellular homeostasis and increasing oxidative stress.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Researchers at University of California - San Francisco designed biological sensors that can ensure engineered cells are activated in tumor environments, making cancer therapies more effective. The new sensors, called SNIPRs, can bind to soluble molecules and alter gene expression, offering a promising approach for targeted therapies.
The review explores the impact of extracellular matrix (ECM) geometry on immune cell behavior and treatment efficacy. Specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), create physical barriers that limit immune cell access to tumors.
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Research discovered that chloride ion channels play a role in glioblastoma cell division and proliferation. By blocking these channels, replication can be stopped, pointing to ion currents as a potential target for therapeutic approaches.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
Researchers at UNIGE and HUG have developed CAR-T cells capable of targeting malignant gliomas while sparing healthy tissue. The treatment uses a specific marker on tumour cells and appears to be effective in controlling tumour growth without signs of toxicity.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
Researchers have successfully visualized and tracked specific cells in deep brain tissue, including along the corpus callosum's nerve fibre highway. This advancement could potentially lead to better diagnostic tools for glioblastoma, a deadly brain cancer.
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
Researchers have discovered that sodium chloride can increase the efficiency of antitumoral T cells, leading to improved metabolic fitness and enhanced tumor killing capabilities. This finding has significant implications for adoptive T-cell therapy in cancer treatment.